Annemiek de Ruiter, MBBS FRCP

Head of Global Medical Sciences
ViiV Healthcare., United Kingdom

Disclosure(s): GSK: Stocks/Bonds (Public Company); ViiV Healthcare: Employee

Poster(s):

• (P-1899) Improvement in Provider Experiences from Baseline to Month 12 with Integrating Cabotegravir Long-Acting (CAB LA) for PrEP into Care in an Implementation Science Trial (PILLAR)
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT